Reports Q1 cash, cash equivalents and short-term investments were $261.9M as of March 31, 2026. Reports Q1 R&D expenses $9.3M vs $4.1M last year. Reports Q1 G&A expenses $5.5M vs $3.8M last year. “Following the positive Phase 3 SELVA topline results, we believe Palvella is on a clear path toward near-term NDA submission for QTORIN rapamycin in microcystic lymphatic malformations, with the potential for approval and U.S. commercial launch in the first half of 2027,” said CEO Wes Kaupinen.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Highlights QTORIN Progress and Financing in Q1 Update
- Palvella Therapeutics doses first patients in LOTU trial
- Palvella Therapeutics Adds Independent Dermatology Expert to Board
- Palvella Showcases QTORIN Platform Momentum and Commercial Readiness
- 3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts